Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Res Social Adm Pharm. 2022 Oct;18(10):3860-3863. doi: 10.1016/j.sapharm.2022.03.009. Epub 2022 Mar 22.
As more biosimilars enter the pharmaceutical market, patient acceptance remains a significant barrier to their uptake. Psychological factors, such as negative expectations, are important causes of patient hesitancy. As a result, patients can develop nocebo responses following a transition, discontinue biosimilar treatment early, or have poor adherence. These negative outcomes may offset some of the cost-saving potential of biosimilars. Key healthcare professionals such as pharmacists, physicians, and nurses already play a noteworthy role in educating and transitioning patients. However, given the psychological aspect of biosimilar acceptance, it is logical for healthcare professionals and researchers to draw on research and theory from health psychology. This commentary outlines how a multidisciplinary approach can add to the understanding of the mechanisms behind patient resistance to biosimilars and help engage patients in the transitioning process. It also explores how health psychology strategies that have been successful in similar areas can be translated to help conduct more effective transitions. Future directions in research are discussed.
随着越来越多的生物类似药进入医药市场，患者的接受度仍然是其推广应用的一个重大障碍。负面预期等心理因素是导致患者犹豫不决的重要原因。因此，患者在转换治疗时可能会产生反安慰剂效应，提前停止生物类似药治疗，或者不遵医嘱。这些负面结果可能会抵消生物类似药的部分成本节约潜力。药剂师、医生和护士等主要医疗保健专业人员已经在教育和帮助患者过渡方面发挥了重要作用。然而，鉴于生物类似药的接受度存在心理方面的因素，医疗保健专业人员和研究人员借鉴健康心理学的研究和理论是合理的。本评论概述了多学科方法如何有助于加深理解患者对生物类似药的抵制背后的机制，并帮助患者参与过渡过程。它还探讨了在类似领域取得成功的健康心理学策略如何被转化为帮助进行更有效的过渡。讨论了未来的研究方向。
